EPHA3

Ephrin type-A receptor 3 · P29320 · EPHA3 on Sugi Atlas →

18,578 patent compounds predicted against EPHA3, 16,157 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Dasatinib Anhydrous (SCHEMBL8226)	1.00	2/20
Dasatinib Anhydrous (SCHEMBL290515)	1.00	2/20
SCHEMBL129615	0.72	2/20
SCHEMBL672223	0.62	2/20
SCHEMBL242042	0.58	2/20
SCHEMBL372043	0.47	2/20
SCHEMBL371717	0.47	2/20
SCHEMBL41486	0.44	2/20
Gefitinib (SCHEMBL7866)	1.00	1/20
Nilotinib (SCHEMBL7901)	1.00	1/20
Erlotinib (SCHEMBL8413)	1.00	1/20
Vandetanib (SCHEMBL9044)	1.00	1/20
Canertinib (SCHEMBL54837)	1.00	1/20
Cediranib (SCHEMBL63147)	1.00	1/20
Quizartinib (SCHEMBL72923)	1.00	1/20
Pelitinib (SCHEMBL93756)	1.00	1/20
Pelitinib (SCHEMBL93757)	1.00	1/20
Doramapimod (SCHEMBL129721)	1.00	1/20
SCHEMBL256712	1.00	1/20
Gefitinib (SCHEMBL465143)	1.00	1/20

Clinical trials — most relevant to EPHA3 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Investigating the Potential Role of Aerosolized Retinoic Acid, a Potent Vitamin A Metabolite for Treating COVID-19 Anosmia and Retinoic Acid Insufficiency .A Novel Approach for Regaining Sense of Smell.	PHASE4	UNKNOWN
Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast Cancer	PHASE1/PHASE2	COMPLETED
Postoperative EGFR-TKI Therapy forContralateral Pulmonary Nodules in Patients With EGFR-Mutant NSCLC（ARMOR2501）	PHASE2	RECRUITING
Safety and Efficacy of the PAINLESS Nerve Growth Factor CHF6467 in Optic Pathway Glioma (OPG)	PHASE2	ACTIVE_NOT_RECRUITING
PiCCA Study (Panitumumab in Combination With Cisplatin/Gemcitabine)	PHASE2	COMPLETED
ASLAN001 in Patients With Advanced or Metastatic Cholangiocarcinoma Who Progressed on at Least 1 Line of Systemic Therapy	PHASE2	COMPLETED
Study of Anlotinib Plus Chemoradiotherapy in Patients With Locally Advanced NSCLC	PHASE1/PHASE2	UNKNOWN
Neoadjuvant GW572016 to Treat Breast Cancer	PHASE2	COMPLETED
Study of a c-Met Inhibitor PLB1001 in Patients With PTPRZ1-MET Fusion Gene Positive Recurrent High-grade Gliomas	PHASE1	COMPLETED
Study of TARCEVA (Erlotinib) as Adjuvant Treatment for Locally Advanced Head and Neck Squamous Cell Carcinoma	PHASE1	COMPLETED
Changes in Skin Innervation of Neurologically Asymptomatic Type 2 Diabetic Patients: the Correlation With the Diabetic Parameters and Neurotrophins.	nan	UNKNOWN
A Retrospective Study to Determine the Incidence of NTRK Fusions. NTRK Study	nan	COMPLETED
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma	nan	COMPLETED
The Roles of Neutrophil Elastase in Lung Cancer	nan	UNKNOWN
Genetics of Arteriovenous Malformations	nan	UNKNOWN
The Role of Gene Changes in Brain Tumor Formation and Growth	nan	COMPLETED
Genetic Study of Newly Diagnosed Central Nervous System Tumors in Young Children	nan	COMPLETED
NTRK 1,2,3 Rearrangements in Patients With Solid Tumors	nan	ACTIVE_NOT_RECRUITING
Clinical Significance of DKK2 Protein in Cerebral Ischemia-reperfusion Injury	nan	UNKNOWN
Expression of CD19 Complex in Lymphoproliferative Disorders	nan	UNKNOWN
Cardiopulmonary Exercise Testing to Evaluate Pulmonary AVMs	nan	COMPLETED
Family Blood Pressure Program - HyperGEN	nan	COMPLETED
Brain Tissue Integrity and Autonomic Function Alterations in Childhood OSA and ADHD, and After Adenotonsillectomy.	nan	UNKNOWN
Rehabilomics Study in Stroke Patients After Robotic Rehabilitation	nan	COMPLETED
The Etiology and Progression of Brain Tumors	nan	COMPLETED
Investigating Phenotypic, Epigenetic, and NeuroGenetic Traits in Rare and Ultra-rare Neurodevelopmental Disorders (Project PENGUIN)	nan	RECRUITING
Genetic Analysis of Attention Deficit Hyperactivity Disorder (ADHD)	nan	COMPLETED
Prospective Monocentric Clinical-biological Database	nan	RECRUITING
Study of the Genetic Factors Involved in Autism and Related Disorders	nan	RECRUITING
Genetic Analysis Using Blood or Bone Marrow From Participants With Neuroblastoma or Noncancerous Conditions	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a EPHA3 binder may also engage these)

Protein	Name	Similarity
O08680	—	1.000	O08680 →
P29319	—	1.000	P29319 →
Q60629	—	1.000	Q60629 →
P29318	—	1.000	P29318 →
P54757	—	1.000	P54757 →
Q90344	—	1.000	Q90344 →
EPHA6	Ephrin type-A receptor 6	1.000	landscape →
EPHA5	Ephrin type-A receptor 5	0.999	landscape →
Q07498	—	0.998	Q07498 →
Q91694	—	0.998	Q91694 →
Q91736	—	0.998	Q91736 →
Q91735	—	0.998	Q91735 →
P54755	—	0.998	P54755 →
Q03137	—	0.997	Q03137 →
Q62413	—	0.997	Q62413 →
Q91571	—	0.997	Q91571 →
Q8CBF3	—	0.997	Q8CBF3 →
O42422	—	0.997	O42422 →
Q91845	—	0.997	Q91845 →
Q07497	—	0.997	Q07497 →
P09759	—	0.997	P09759 →
P54758	—	0.996	P54758 →
Q03145	—	0.995	Q03145 →
EPHA4	Ephrin type-A receptor 4	0.995	landscape →
EPHA7	Ephrin type-A receptor 7	0.995	landscape →
Q07496	—	0.994	Q07496 →
P54759	—	0.994	P54759 →
Q02858	—	0.994	Q02858 →
P54763	—	0.994	P54763 →
EPHB2	Ephrin type-B receptor 2	0.994	landscape →